Skip to main content
Premium Trial:

Request an Annual Quote

Protein Biomarker Firm Astute Medical Completes $40.4M Series C Round

NEW YORK (GenomeWeb News) – Protein biomarker diagnostics firm Astute Medical today announced the completion of a Series C financing round that raised $40.4 million.

The funding will go toward the commercialization of Astute's first product and to expand its research, development, and validation of biomarker-based laboratory tests.

The round was led by MPM Capital and new investor Kaiser Permanente Ventures. Other participants included De Novo Ventures, Delphi Ventures, Domain Associates, and Johnson & Johnson Development.

In March 2011 the San Diego-based company raised $13 million in an extension of a Series B round that previously brought in $26.5 million. Astute took in $6.2 million in a Series A round in 2008.

The firm identifies and validates protein biomarkers for the development of diagnostic tests. Its focus is on community- and hospital-acquired acute conditions and current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more